Released May 8, 2025, after the close
10-Q filed May 8, 2025, 38 days after period end · 0001516551-25-000042
Q1 2025 · 10-Q
Revenue—
Net Income-$11.10M-$11.10M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$0.28-$0.28 N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$11,759,562N/M
Operating Cash Flow-$9,185,480N/M
Free Cash Flowderived-$9,191,792N/M
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Income | -$11.10M | -$5.02M | -$5.17M | -$3.04M |
| EPS Diluted | -$0.28 | -$0.18 | -$1.37 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR